What we claim is:

1. A compound of matter having the formula:



wherein R^1 is $-CH_2OH$, $-C(=O)NR^5R^6$;

R^2 is selected from the group consisting of hydrogen, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, NO_2, heterocyclyl, aryl, heteroaryl, CF_3, CN, OR^{20}, SR^{20}, $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, $SO_2NR^{20}COR^{22}$, $SO_2NR^{20}CO_2R^{22}$, $SO_2NR^{20}CON(R^{20})_2$, $N(R^{20})_2$ $NR^{20}COR^{22}$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, $NR^{20}C(NR^{20})NHR^{23}$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, $CONR^{20}SO_2R^{22}$, $NR^{20}SO_2R^{22}$, $SO_2NR^{20}CO_2R^{22}$, $OCONR^{20}SO_2R^{22}$, $OC(O)R^{20}$, $C(O)OCH_2OC(O)R^{20}$, and $OCON(R^{20})_2$ and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, NO_2, alkyl, CF_3, amino, mono- or di- alkylamino, alkyl or aryl or heteroaryl amide, $NCOR^{22}$, $NR^{20}SO_2R^{22}$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, $NR^{20}CON(R^{20})_2$, $OC(O)R^{20}$, $OC(O)N(R^{20})_2$, SR^{20}, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, CN, and OR^{20};

R^3, R^4 are each individually selected from the group consisting of hydrogen, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, and heteroaryl, halo, NO_2, CF_3, CN, OR^{20}, SR^{20}, $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, $SO_2NR^{20}COR^{22}$, $SO_2NR^{20}CO_2R^{22}$, $SO_2NR^{20}CON(R^{20})_2$, $N(R^{20})_2$ $NR^{20}COR^{22}$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, $NR^{20}C(NR^{20})NHR^{23}$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, $CONR^{20}SO_2R^{22}$, $NR^{20}SO_2R^{22}$, $SO_2NR^{20}CO_2R^{22}$, $OCONR^{20}SO_2R^{22}$, $OC(O)R^{20}$, $C(O)OCH_2OC(O)R^{20}$, and $OCON(R^{20})_2$ wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, NO_2, heterocyclyl, aryl, heteroaryl, CF_3, CN, OR^{20}, SR^{20}, $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, $SO_2NR^{20}COR^{22}$,

$SO_2NR^{20}CO_2R^{22}$, $SO_2NR^{20}CON(R^{20})_2$, $N(R^{20})_2$ $NR^{20}COR^{22}$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, $NR^{20}C(NR^{20})NHR^{23}$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, $CONR^{20}SO_2R^{22}$, $NR^{20}SO_2R^{22}$, $SO_2NR^{20}CO_2R^{22}$, $OCONR^{20}SO_2R^{22}$, $OC(O)R^{20}$, $C(O)OCH_2OC(O)R^{20}$, and $OCON(R^{20})_2$ and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, NO_2, alkyl, CF_3, amino, mono- or di- alkylamino, alkyl or aryl or heteroaryl amide, $NCOR^{22}$, $NR^{20}SO_2R^{22}$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, $NR^{20}CON(R^{20})_2$, $OC(O)R^{20}$, $OC(O)N(R^{20})_2$, SR^{20}, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, CN, and OR^{20};

R^5 and R^6 are each individually selected from H, $C_{1\text{-}15}$ alkyl with from 1 to 2 substituents independently selected from the group consisting of halo, NO_2, heterocyclyl, aryl, heteroaryl, CF_3, CN, OR^{20}, SR^{20}, $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, $SO_2NR^{20}COR^{22}$, $SO_2NR^{20}CO_2R^{22}$, $SO_2NR^{20}CON(R^{20})_2$, $N(R^{20})_2$ $NR^{20}COR^{22}$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, $NR^{20}C(NR^{20})NHR^{23}$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, $CONR^{20}SO_2R^{22}$, $NR^{20}SO_2R^{22}$, $SO_2NR^{20}CO_2R^{22}$, $OCONR^{20}SO_2R^{22}$, $OC(O)R^{20}$, $C(O)OCH_2OC(O)R^{20}$, and $OCON(R^{20})_2$, and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, NO_2, alkyl, CF_3, amino, mono- or di- alkylamino, alkyl or aryl or heteroaryl amide, $NCOR^{22}$, $NR^{20}SO_2R^{22}$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, $NR^{20}CON(R^{20})_2$, $OC(O)R^{20}$, $OC(O)N(R^{20})_2$, SR^{20}, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, CN, and OR^{20};

R^{20} is selected from the group consisting of H, $C_{1\text{-}15}$ alkyl, $C_{2\text{-}15}$ alkenyl, $C_{2\text{-}15}$ alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN, O-$C_{1\text{-}6}$ alkyl, CF_3, aryl, and heteroaryl; and

R^{22} is a member selected from the group consisting of $C_{1\text{-}15}$ alkyl,$C_{2\text{-}15}$ alkenyl, $C_{2\text{-}15}$ alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN, O-$C_{1\text{-}6}$ alkyl, CF_3, and heteroaryl wherein, when R^1 is CH_2OH, and R^3 is H and R^4 is H, and the pyrazole ring is attached through C^4, then R^2 is not H.

2. The compound of claim 1 wherein R^2 is selected from the group consisting of hydrogen, $C_{1\text{-}15}$ alkyl, $C_{2\text{-}15}$ alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, NO_2, heterocyclyl, aryl, heteroaryl, CF_3, CN, OR^{20}, SR^{20}, $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is

optionally substituted with halo, alkyl, CF_3 CN, and OR^{20};

R^3 and R^4 are each individually selected from the group consisting of hydrogen, C_{1-15} alkyl, C_{2-15} alkynyl, heterocyclyl, aryl, heteroaryl, halo, NO_2, CF_3, CN, OR^{20}, SR^{20}, $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, wherein the alkyl, alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, NO_2, heterocyclyl, aryl, heteroaryl, CF_3, CN, OR^{20}, SR^{20}, $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22}, $SO_2N(R^{20})_2$, COR^{20}, CO_2R^{20}, $CON(R^{20})_2$, and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, alkyl, CF_3 CN, and OR^{20};

R^5 and R^6 are each individually selected from H, and C_{1-15} alkyl having from 1 to 2 substituents independently selected from the group consisting of aryl, heteroaryl, CF_3, OR^{20}, and wherein each optional heteroaryl, and aryl substituent is further optionally substituted with halo, alkyl, and CF_3;

R^{20} is a member selected from the group consisting of H, C_{1-6} alkyl, aryl, and heteroaryl; and

R^{22} is a member selected from the group consisting of C_{1-6} alkyl, aryl, and heteroaryl, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from halo, alkyl, CN, O-C_{1-6} alkyl, and CF_3.

3. The compound of claim 1 wherein R^2 is selected from the group consisting of hydrogen, C_{1-15} alkyl, C_{2-15} aryl, and heteroaryl, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, CF_3, CN, OR^{20}, SR^{20}, $S(O)R^{22}$, CO_2R^{20}, $CON(R^{20})_2$, and wherein each optional heteroaryl, and aryl substituent is optionally substituted with halo, alkyl, CF_3 CN, and OR^{20};

R^3 and R^4 are each individually selected from the group consisting of hydrogen, C_{1-15} alkyl, C_{2-15} aryl, heteroaryl, halo, CF_3, CN, OR^{20}, SR^{20}, $S(O)R^{22}$, CO_2R^{20}, and $CON(R^{20})_2$, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, aryl, heteroaryl, CF_3, CN, OR^{20}, SR^{20}, $S(O)R^{22}$, CO_2R^{20}, and $CON(R^{20})_2$, and wherein each optional heteroaryl, and aryl substituent is optionally substituted with halo, alkyl, CF_3 CN, and OR^{20};

R^5 and R^6 are each individually selected from H, and C_{1-15} alkyl having from 1 to 2 substituents selected from CF_3;

R^{20} is selected from H, and C_{1-6}; and

R^{22} is C_{1-6} alkyl.

4. The compound of claim 1 wherein R^2 is independently selected from the group consisting of hydrogen, C_{1-15} alkyl, C_{2-15} aryl, and heteroaryl, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, heteroaryl, CF_3, CN, OR^{20}, CO_2R^{20}, and $CON(R^{20})_2$, and wherein each optional heteroaryl, and aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN;

R^3 and R^4 are each individually selected from the group consisting of hydrogen, C_{1-15} alkyl, C_{2-15} aryl, heteroaryl, halo, CF_3, CN, OR^{20}, CO_2R^{20}, and $CON(R^{20})_2$, wherein the alkyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, heteroaryl, CF_3, CN, OR^{20}, CO_2R^{20}, and $CON(R^{20})_2$, and wherein each optional heteroaryl, and aryl substituent is optionally substituted with halo, alkyl, CF_3 or CN;

R^5 and R^6 are each individually selected from H, and C_{1-15} alkyl;

R^{20} is selected from H, and C_{1-6}; and

R^{22} is C_{1-6} alkyl.

5. The compound of claim 1 wherein R^2 is independently selected from the group consisting of hydrogen, C_{1-15} alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, OR^{20}, aryl, CF_3, CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 or CN;

R^3 and R^4 are each individually selected from the group consisting of hydrogen, C_{1-15} alkyl, aryl, halo, CF_3, and CN, wherein the alkyl, and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, CF_3, CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 or CN;

R^5 and R^6 are each individually selected from H, and C_{1-15} alkyl; and

R^{20} is selected from H, and C_{1-6}.

6. The compound of claims 1 or 2 or 3 or 4 or 5 having the following formula wherein the point of attachment of the pyrazole ring is C-4.



7. The compound of claims 1 or 2 or 3 or 4 or 5 having the following formula wherein the point of attachment of the pyrazole ring is C-3.



8. The compound of claims 1 or 2 or 3 or 4 or 5 having the following formula wherein the point of attachment of the pyrazole ring is C-5.



9. The compound of claims 6 or 7 or 8 wherein $R^1 = CH_2OH$;

10. The compound of claim 6 wherein R^1 is $-CH_2OH$;

R^2 is independently selected from the group consisting of hydrogen, C_{1-10} alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, OR^{20}, aryl, CF_3, and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN;

R^3 and R^4 are each individually- selected from the group consisting of hydrogen, C_{1-15} alkyl, aryl, halo, CF_3, and CN, wherein the alkyl, and aryl substituents are optionally substituted with a substituent independently selected from the group consisting of halo, CF_3, and CN; and

R^{20} is selected from H, and C_{1-6} alkyl;

11. The compound of claim 6 wherein R^1 is $-CH_2OH$;

R^2 is independently selected from the group consisting of hydrogen, C_{1-8} alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, OR^{20}, aryl, CF_3, and

CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN;

R^3 and R^4 are each individually selected from the group consisting of hydrogen, C_{1-3} alkyl, aryl, halo, CF_3, CN; and

R^{20} is selected from H, and C_{1-6} alkyl.

12. The compound of claim 6 wherein R^1 is $-CH_2OH$;

R^2 is independently selected from the group consisting of hydrogen, C_{1-8} alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, OR^{20}, aryl, CF_3, and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN;

R^3 and R^4 are each individually selected from the group consisting of hydrogen, methyl, and halo; and

R^{20} is selected from H, and C_{1-6};

13. The compound of claim 6 wherein R^1 is $-CH_2OH$;

R^2 is independently selected from the group consisting of hydrogen, C_{1-8} alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, aryl, CF_3, and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN; and

R^3 and R^4 are each individually selected from the group consisting of hydrogen, and methyl.

14. The compound of claim 6 wherein R^1 is $-CH_2OH$;

R^2 is selected from the group consisting of hydrogen, and C_{1-8} alkyl that is optionally substituted with 1 substituent selected from the group consisting of aryl, CF_3, and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN; and

R^3 and R^4 are each individually selected from the group consisting of hydrogen, and methyl.

15. The compound of claim 6 wherein R^1 is $-CH_2OH$;

R^2 is selected from the group consisting of hydrogen, and C_{1-8} alkyl that is optionally substituted with one aryl substituent that is optionally substituted with halo, alkyl, CF_3 and CN; and

R^3 and R^4 are each hydrogen.

16. The compound of claim 6 wherein R^1 is $-CH_2OH$;

R^2 is selected from the group consisting of hydrogen, and C_{1-6} alkyl that is optionally substituted with aryl that is optionally substituted with alkyl; and

R^3 and R^4 are each hydrogen.

17. The compound of claim 7 wherein R^1 is $-CH_2OH$;

R^2 is selected from the group consisting of hydrogen, and C_{1-8} alkyl that is optionally substituted with 1 substituent selected from the group consisting of aryl, CF_3, and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN; and

R^3 and R^4 are each individually selected from hydrogen, and methyl.

18. The compound of claim 7 wherein R^1 is $-CH_2OH$;

R^2 is selected from the group consisting of hydrogen, and C_{1-8} alkyl that is optionally substituted with 1 substituent selected from the group consisting of aryl, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN; and

R^3 and R^4 are each hydrogen.

19. The compound of claim 7 wherein R^1 is $-CH_2OH$;

R^2 is selected from the group consisting of hydrogen, and C_{1-6} alkyl that is optionally substituted with aryl that is optionally substituted with alkyl; and

R^3 and R^4 are each hydrogen.

20. The compound of claim 8 wherein R^1 is $-CH_2OH$;

R^2 is selected from the group consisting of hydrogen, and C_{1-6} alkyl;

R^3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, and aryl, wherein the alkyl, and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, aryl, CF_3, and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN; and

R^4 is selected from the group consisting of hydrogen and C_{1-6} alkyl.

21. The compound of claim 8 wherein R^1 is $-CH_2OH$;

R^2 is selected from the group consisting of hydrogen, and methyl;

R^3 and R^4 are each independently selected from the group consisting of hydrogen, and C_{1-6} alkyl, that is optionally substituted with aryl that is optionally substituted with alkyl; and

R^4 is selected from hydrogen and methyl.

22. The compound of claim 6 wherein R^1 is –CONHEt;

R^2 is selected from the group consisting of hydrogen, and C_{1-8} alkyl that is optionally substituted with 1 substituent selected from the group consisting of aryl, CF_3, and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF_3 and CN;

and

R^3 and R^4 are each individually selected from the group consisting of hydrogen, and methyl.

23. The compound of claim 6 wherein R^1 is –CONHEt;

R^2 is selected from the group consisting of hydrogen, and C_{1-8} alkyl that is optionally substituted with 1 aryl substituent of aryl, that is optionally substituted with halo, alkyl, CF_3 and CN; and

R^3 and R^4 are each hydrogen.

24. The compound of claim 6 wherein R^1 is –CONHEt;

R^2 is selected from the group consisting of hydrogen, and C_{1-6} alkyl that is optionally substituted with aryl that is optionally substituted with alkyl; and

R^3 and R^4 are hydrogen.

25. The compound of claim 7 wherein R^1 is –CONHEt;

R^2 is selected from the group consisting of hydrogen, and C_{1-8} that is optionally substituted with 1 aryl substituent that is optionally substituted with halo, alkyl, CF_3 and CN; and

R^3 and R^4 are hydrogen.

26. The compound of claim 7 wherein R^1 is –CONHEt;

R^2 is independently selected from the group consisting of hydrogen, and C_{1-6} alkyl that is optionally substituted with aryl that is optionally substituted with alkyl; and

R^3 and R^4 are each hydrogen.

27. The compound of claim 8 wherein R^1 is –CONHEt; and

R^2 is selected from hydrogen, and methyl;

R^3 and R^4 are each individually selected from the group consisting of hydrogen, and C_{1-6} alkyl, wherein the alkyl, is optionally substituted with aryl that is optionally substituted with alkyl; and

R^4 is selected from hydrogen and methyl.

28. The compound of claim 1 wherein the compound is selected from (4S,2R,3R,5R)-2-{6-amino-2-[1-benzylpyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9yl]-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-[6-amino-2-(1-methylpyrazol-4-yl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(methylethyl)pyrazol-4-

yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(3-phenylpropyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(4-t-butylbenzyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-(6-amino-2-pyrazol-4-ylpurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-pent-4-enylpyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-decylpyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(cyclohexylmethyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(2-phenylethyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(3-cyclohexylpropyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, (4S,2R,3R,5R)-2-{6-amino-2-[1-(2-cyclohexylethyl)pyrazol-4-yl]purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol, and mixtures thereof.

29. A method for stimulating coronary vasodilatation in a mammal by administering to the mammal a therapeutically effective amount of a compound of claim 1 that is sufficient to stress the heart and induce a coronary steal situation for the purposes of imaging the heart.

30. The method of claim 25 wherein the therapeutically effective amount ranges from about 0.01 to about 100 mg/kg weight of the mammal.

31. The method of claim 29 wherein the mammal is a human.

32. A pharmaceutical composition of matter comprising the compound of claim 1 and one or more pharmaceutical excipients.

33. The pharmaceutical composition of matter of claim 32 wherein the pharmaceutical composition is in the form of a solution.

34. The pharmaceutical composition of matter of claim 32 wherein the composition is useful as an anti-inflammatory, in adjunctive therapy with angioplasty, as a platelet aggregation inhibitor, and as an inhibitor of platelet and neutrophil activation.